159 related articles for article (PubMed ID: 38039351)
1. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
Packard CJ; Pirillo A; Tsimikas S; Ference BA; Catapano AL
Cardiovasc Res; 2024 Feb; 119(18):2843-2857. PubMed ID: 38039351
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Norata GD; Tsimikas S; Pirillo A; Catapano AL
Trends Pharmacol Sci; 2015 Oct; 36(10):675-687. PubMed ID: 26435212
[TBL] [Abstract][Full Text] [Related]
3. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
4. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
5. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
6. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
7. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
9. [Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events].
Pirillo A; Catapano AL
G Ital Cardiol (Rome); 2015 May; 16(5):289-94. PubMed ID: 25994465
[TBL] [Abstract][Full Text] [Related]
10. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Borén J; Packard CJ; Taskinen MR
Front Endocrinol (Lausanne); 2020; 11():474. PubMed ID: 32849270
[TBL] [Abstract][Full Text] [Related]
11. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.
Taskinen MR; Björnson E; Matikainen N; Söderlund S; Rämö J; Ainola MM; Hakkarainen A; Sihlbom C; Thorsell A; Andersson L; Bergh PO; Henricsson M; Romeo S; Adiels M; Ripatti S; Laakso M; Packard CJ; Borén J
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040803
[TBL] [Abstract][Full Text] [Related]
12. Targeting ApoC-III to Reduce Coronary Disease Risk.
Khetarpal SA; Qamar A; Millar JS; Rader DJ
Curr Atheroscler Rep; 2016 Sep; 18(9):54. PubMed ID: 27443326
[TBL] [Abstract][Full Text] [Related]
13. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
15. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
17. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
[TBL] [Abstract][Full Text] [Related]
18. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY; Kim NH
J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein C-II: the re-emergence of a forgotten factor.
Wolska A; Reimund M; Remaley AT
Curr Opin Lipidol; 2020 Jun; 31(3):147-153. PubMed ID: 32332429
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]